Rodrigo Alonso1,2, Rosa Argüeso3, Pilar Álvarez-Baños4, Ovidio Muñiz-Grijalvo5, Jose Luis Diaz-Diaz6, Pedro Mata7. 1. Center for Advanced Metabolic Medicine and Nutrition, Av. Las Condes 9460, of 501. , Santiago, Chile. rodrigoalonsok@gmail.com. 2. Fundación Hipercolesterolemia Familiar, Madrid, Spain. rodrigoalonsok@gmail.com. 3. Department of Endocrinology, Hospital Universitario Lucus Augusti, Lugo, Spain. 4. Department of Endocrinology, Hospital Universitario de Burgos, Burgos, Spain. 5. Internal Medicine Department, Hospital Virgen del Rocío, Sevilla, Spain. 6. Internal Medicine Department, Hospital Abente Y Lago, A Coruña, Spain. 7. Fundación Hipercolesterolemia Familiar, Madrid, Spain.
Abstract
PURPOSE OF REVIEW: Familial hypercholesterolemia is a high cardiovascular risk disorder. We will review the role of lipoprotein(a) in cardiovascular risk and in aortic valve stenosis in familial hypercholesterolemia, as well as its association with their phenotype, and strategies to identify this high-risk population. RECENT FINDINGS: Patients with familial hypercholesterolemia have higher lipoprotein(a) levels mainly due to an increased frequency of LPA variants, and the cardiovascular risk is increased twofolds when both conditions coexist. Also, an increased risk for aortic valve stenosis and valve replacement has been observed with high lipoprotein(a) levels. Assessment of lipoprotein(a) during the cascade screening for familial hypercholesterolemia is a good opportunity to identify this high-risk population. High cardiovascular risk in familial hypercholesterolemia is increased even more when lipoprotein(a) is also elevated. Measurement of lipoprotein(a) in these patients is crucial to identify those subjects who need to intensify LDL-cholesterol reduction pending availability of lipoprotein(a)-specific treatments.
PURPOSE OF REVIEW: Familial hypercholesterolemia is a high cardiovascular risk disorder. We will review the role of lipoprotein(a) in cardiovascular risk and in aortic valve stenosis in familial hypercholesterolemia, as well as its association with their phenotype, and strategies to identify this high-risk population. RECENT FINDINGS: Patients with familial hypercholesterolemia have higher lipoprotein(a) levels mainly due to an increased frequency of LPA variants, and the cardiovascular risk is increased twofolds when both conditions coexist. Also, an increased risk for aortic valve stenosis and valve replacement has been observed with high lipoprotein(a) levels. Assessment of lipoprotein(a) during the cascade screening for familial hypercholesterolemia is a good opportunity to identify this high-risk population. High cardiovascular risk in familial hypercholesterolemia is increased even more when lipoprotein(a) is also elevated. Measurement of lipoprotein(a) in these patients is crucial to identify those subjects who need to intensify LDL-cholesterol reduction pending availability of lipoprotein(a)-specific treatments.
Authors: Rodrigo Alonso; Eduardo Andres; Nelva Mata; Francisco Fuentes-Jiménez; Lina Badimón; José López-Miranda; Teresa Padró; Ovidio Muñiz; Jose Luis Díaz-Díaz; Marta Mauri; Jose María Ordovás; Pedro Mata Journal: J Am Coll Cardiol Date: 2014-03-13 Impact factor: 24.094
Authors: Anne Langsted; Pia R Kamstrup; Marianne Benn; Anne Tybjærg-Hansen; Børge G Nordestgaard Journal: Lancet Diabetes Endocrinol Date: 2016-05-13 Impact factor: 32.069
Authors: E J Sijbrands; R G Westendorp; M Paola Lombardi; L M Havekes; R R Frants; J J Kastelein; A H Smelt Journal: Atherosclerosis Date: 2000-04 Impact factor: 5.162
Authors: R Vongpromek; S Bos; G-J R Ten Kate; R Yahya; A J M Verhoeven; P J de Feyter; F Kronenberg; J E Roeters van Lennep; E J G Sijbrands; M T Mulder Journal: J Intern Med Date: 2015-01-05 Impact factor: 8.989
Authors: Leopoldo Pérez de Isla; Rodrigo Alonso; Nelva Mata; Adriana Saltijeral; Ovidio Muñiz; Patricia Rubio-Marin; José L Diaz-Diaz; Francisco Fuentes; Raimundo de Andrés; Daniel Zambón; Jesús Galiana; Mar Piedecausa; Rocio Aguado; Daniel Mosquera; José I Vidal; Enrique Ruiz; Laura Manjón; Marta Mauri; Teresa Padró; José P Miramontes; Pedro Mata Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-21 Impact factor: 8.311
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: R Alonso; N Mata; S Castillo; F Fuentes; P Saenz; O Muñiz; J Galiana; R Figueras; J L Diaz; P Gomez-Enterría; M Mauri; M Piedecausa; L Irigoyen; R Aguado; P Mata Journal: Atherosclerosis Date: 2008-02-20 Impact factor: 5.162
Authors: Leopoldo Pérez de Isla; Gerald F Watts; Rodrigo Alonso; José Luis Díaz-Díaz; Ovidio Muñiz-Grijalvo; Daniel Zambón; Francisco Fuentes; Raimundo de Andrés; Teresa Padró; José López-Miranda; Pedro Mata Journal: Eur Heart J Date: 2021-06-07 Impact factor: 29.983
Authors: Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen Journal: Eur Heart J Date: 2010-10-21 Impact factor: 29.983